Company / Cash & Equivalents
Actinium Pharmaceuticals, Inc. Cash & Equivalents History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$48.0M
FY2025
5-year range
$48.0M / $108.9M
FY2021-FY2025
Trend
-34.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 3 consecutive years, from $109M in FY2022 to $48M in FY2025.
Based on SEC 10-K filings.
$48M in FY2025 with a 3-year CAGR of -23.9%.
Declined from $77M to $48M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -23.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Actinium Pharmaceuticals, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 3-year CAGR of -23.9%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 34.2% year-over-year.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $48.0M | -34.2% |
| FY2024 | $72.9M | -4.9% |
| FY2023 | $76.7M | -29.6% |
| FY2022 | $108.9M | +39.9% |
| FY2021 | $77.8M | +1264.5% |
| FY2011 | $5.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026